Abstract:Abstract Background Rare Eye Diseases (RED) are the leading cause of visual impairment and blindness for children and young adults in Europe. This heterogeneous group of conditions includes over 900 disorders ranging from relatively prevalent disorders such as retinitis pigmentosa to very rare entities such as developmental eye anomalies. A significant number of patients with RED have an underlying genetic etiology. One of the aims of the European Reference Network for Rare Eye Diseases (ERN–EYE) is to facilitate improvement in diagnosis of RED in European member states. Main body Technological advances have allowed genetic and genomic testing for RED. The outcome of genetic testing allows better understanding of the condition and allows reproductive and therapeutic options. The increase of the number of clinical trials for RED has provided urgency for genetic testing in RED. A survey of countries participating in ERN-EYE demonstrated that the majority are able to access some forms of genomic testing. However, there is significant variability, particularly regarding testing as part of clinical service. Some countries have a well-delineated rare disease pathway and have a national plan for rare diseases combined or not with a national plan for genomics in medicine. In other countries, there is a well-established organization of genetic centres that offer reimbursed genomic testing of RED and other rare diseases. Clinicians often rely upon research-funded laboratories or private companies. Notably, some member states rely on cross-border testing by way of an academic research project. Consequently, many clinicians are either unable to access testing or are confronted with long turnaround times. Overall, while the cost of sequencing has dropped, the cumulative cost of a genomic testing service for populations remains considerable. Importantly, the majority of countries reported healthcare budgets that limit testing. Short conclusion Despite technological advances, critical gaps in genomic testing remain in Europe, especially in smaller countries where no formal genomic testing pathways exist. Even within larger countries, the existing arrangements are insufficient to meet the demand and to ensure access. ERN-EYE promotes access to genetic testing in RED and emphasizes the clinical need and relevance of genetic testing in RED.

Clinical and genetic characterization of patients with eye diseases included in the Spanish Rare Diseases Patient Registry

The socioeconomic epidemiology of inherited retinal diseases in Portugal

Special Issue "Diagnosis and Treatment of Rare Diseases"

Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study

Genomic Landscape of Sporadic Retinitis Pigmentosa: Findings from 877 Spanish Cases

Syndromic Retinitis Pigmentosa: A 15-Patient Study

Mutational Profile and Retinal Phenotypes of PCARE-Related Cone-Rod Dystrophies in a Mexican Cohort

Mutational Spectrum in 103 Families from a Spanish Cohort

Current management of inherited retinal degenerations in Portugal (IRD-PT survey)

Diagnostic and Therapeutic Consequences

Genetic susceptibility for retinopathy of prematurity and its associated comorbidities

The need for widely available genomic testing in rare eye diseases: an ERN-EYE position statement

Rare bleeding disorders: Real-world data from a Spanish tertiary hospital

Identification and characterization of a new pathologic mutation in a large Leber hereditary optic neuropathy pedigree

[Rare diseases and undiagnosed diseases: advances in neurodevelopment]

Haemoglobinopathies and other rare anemias in Spain: ten years of a nationwide registry (REHem-AR)

Spectrum of variants associated with inherited retinal dystrophies in Northeast Mexico

Genetic profile of syndromic retinitis pigmentosa in Portugal

Multi-omics analysis in human retina uncovers ultraconserved cis-regulatory elements at rare eye disease loci

Panel-based NGS Reveals Novel Pathogenic Mutations in Autosomal Recessive Retinitis Pigmentosa

Colombian Ocular Diseases Epidemiology Study (CODES): Prevalence and Sociodemographic Characterization of Refractive Errors in Colombian Eye Care Consultations